Biotheus is a clinical-stage biotech company focused on the discovery and development of biologics for oncology and inflammatory diseases.

Biotheus

Biotheus Inc. | 1,314 followers on LinkedIn. To Inspire Each Other and Create Effective Medicines for Humankind | Biotheus (普米斯生物技术) aims to discover and develop effective therapeutic biologics for patients with cancer and inflammatory disease. We believe in creative scientific and industrial/academic collaborations in order to reach this common goal.

Vice President Business Development & Licensing ex-China

Roland Meisel, Ph.D.

Executive Director, GM of Nantong Site

Bingyan He

Healthcare investment in Cowin Venture Capital

Jason (Hai) Jiang

Biotheus - BD Senior Manager

Yanli Du

Biotheus Inc.

We are thrilled to celebrate the grand opening of our biologics (DS/DP) manufacturing facility in Nantong 🎉. At this state-of-the-art facility, we have 3 x 2000L lines dedicated to supporting the global development of our pipeline. #Biologics #Manufacturing

Andy T.

Bispecific antibodies, a novel class of immunotherapies, are showing significant promise in oncology. These engineered antibodies can simultaneously bind to two different antigens, providing unique mechanisms of action. Hematological malignancies are the primary focus of bispecific antibody development. Fast forward to 2022–2023, and we witnessed a dynamic shift, with eight new bispecific approvals, primarily revolutionizing hematological cancer treatments. Nevertheless, numerous bispecific antibodies are under investigation for various solid tumors, including gastric, colorectal, ovarian, prostate, and Lung cancer. Immunocore , Innovent Biologics , Johnson & Johnson Innovative Medicine , Roche , Curonix , Genmab , AbbVie , Merus N.V. , Summit Therapeutics, Inc. , BioNTech SE , Affimed , Biotheus Inc. , Amgen , Regeneron , Qilu Pharmaceuticals , and others showcased their latest research and advancements in bispecific treatments at the American Society of Clinical Oncology (ASCO) 2024. Get an in-depth analysis of bispecific antibodies coverage from the ASCO 2024 conference at https://lnkd.in/gwDBMuqP

DelveInsight Business Research LLP

We have strengthened our partnership with Hansoh Pharmaceuticals on PM1080/HS-20117, a EGFR x cMET bispecific, for development of an ADC product. I would like to thank the team at Hansoh for believing in the potential of PM1080 and excited by their vision in the ADC space. Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Biotheus Inc.

Meet our senior team in San Francisco for JPM2024!

Metric
Company Name	Biotheus
Symbol
MSH ID	COM:BIOTHEUS
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Biotechnology
Country	CN
Stage
Employee Count
Website	biotheus.com
LinkedIn	biotheus
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

BIOT

COM:BIOTHEUS

Biotheus

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue